-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Beijing Daxing District has issued "Several Measures to Promote the Development of Pharmaceutical and Health Industry in Daxing District (Trial)"
.
It is understood that the "Measures" clarify that Daxing District will provide up to 300 million yuan in financial support for the implementation of major achievements and innovative resources such as projects that have achieved core technological breakthroughs in the pharmaceutical field
.
Up to 100 million yuan of financial support will be given to the research and development of innovative drugs each year
.
For projects such as the development of cross-integration new business formats in emerging technology fields such as medicine, health and artificial intelligence, we will give up to 10 million yuan in financial support
.
In addition, it also made it clear that it will pay for the annual main business revenue to reach 500 million yuan (inclusive), or the annual output value of single-variety products for the first time to exceed 500 million yuan, 1 billion yuan, 2 billion yuan, or obtain domestic and foreign Qualification certification pharmaceutical companies and institutions shall provide certain financial support and other content respectively
.
The industry believes that the release of this policy will continue to promote the development of innovative drugs in Daxing District and accelerate the technological innovation of the medical device industry, and undertake the achievements of Beijing and global scientific and technological innovations, continue to attract domestic and international high-quality resources, and achieve a high-quality cluster of the pharmaceutical and health industry in Daxing District Style development
.
In fact, in recent years, the overall development momentum of China's pharmaceutical industry has been good.
The industry has previously predicted that during the "14th Five-Year Plan" period, China's pharmaceutical industry will usher in a period of policy dividend opportunities
.
From the current point of view, Daxing District is only a microcosm of the promotion of the further development of the pharmaceutical industry in China, and various localities are currently issuing policies that are beneficial to the development of the pharmaceutical industry
.
For example, on November 1, Jiangsu Province’s "Several Policy Measures on Promoting the High-Quality Development of the Provincial Biomedical Industry" was formally implemented, which clearly stated that in the next three years, it will provide financial support for the innovation of biomedical enterprises in the province
.
For example, in the development of new drugs, different levels of support will be given to innovative drugs and improved new drugs according to different clinical trial stages and marketing production stages; clinical research will be included in the performance evaluation of medical institutions, and for hospitals that have obtained the qualifications of clinical trial institutions, by 2024 In 2010, the proportion of clinical research beds in the total number of hospital beds increased to about 10%; support the introduction of the world’s best talents and teams, and project funding of up to 100 million yuan
.
On November 19, Shenzhen also announced the "Several Measures for Promoting the Development of Biomedical Industry Clusters in Shenzhen (Draft for Solicitation of Comments)" (hereinafter referred to as "Several Measures")
.
"Several Measures" show that Shenzhen will consolidate the support capacity of industrial infrastructure, improve product development support, strengthen clinical research transformation and medical-enterprise collaboration, accelerate the process of medical approval, enhance the "Made in Shenzhen" capability, and accelerate the application and promotion of innovative products.
Strengthen industrial clusters
.
In order to further encourage product development and manufacturing, "Several Measures" also clearly stated that it will increase product development support and focus on breaking new targets.
Chemical drugs, antibody drugs, gene therapy drugs, cell therapy drugs, peptide drugs and enzyme engineering, AI drug development chips Such core technologies, using the "horse racing system", "revealing the list system" and other methods, support enterprises to cooperate with universities and scientific research institutes to carry out "stuck neck" technical research.
Funding will be based on 40% of the total project investment, and the maximum will not exceed 300 million yuan
.
It should be noted that while the pharmaceutical industry is ushering in an increasingly broad market prospect, the industry believes that the challenges it faces will continue to increase
.
For example, the regulation faced by the pharmaceutical industry is becoming more stringent
.
It is reported that medicines are important products related to the health of the people, and it has become the consensus of all regions to strengthen supervision over them
.
Especially after the release of policies such as the withdrawal of GMP, GSP certification, and the "Measures for Unannounced Inspection of Drugs and Medical Devices" in 2019, it can be clearly seen that the country and even local governments are also moving towards standardization in all aspects of drug research and development to sales.
Accelerate development
.
.
It is understood that the "Measures" clarify that Daxing District will provide up to 300 million yuan in financial support for the implementation of major achievements and innovative resources such as projects that have achieved core technological breakthroughs in the pharmaceutical field
.
Up to 100 million yuan of financial support will be given to the research and development of innovative drugs each year
.
For projects such as the development of cross-integration new business formats in emerging technology fields such as medicine, health and artificial intelligence, we will give up to 10 million yuan in financial support
.
In addition, it also made it clear that it will pay for the annual main business revenue to reach 500 million yuan (inclusive), or the annual output value of single-variety products for the first time to exceed 500 million yuan, 1 billion yuan, 2 billion yuan, or obtain domestic and foreign Qualification certification pharmaceutical companies and institutions shall provide certain financial support and other content respectively
.
The industry believes that the release of this policy will continue to promote the development of innovative drugs in Daxing District and accelerate the technological innovation of the medical device industry, and undertake the achievements of Beijing and global scientific and technological innovations, continue to attract domestic and international high-quality resources, and achieve a high-quality cluster of the pharmaceutical and health industry in Daxing District Style development
.
In fact, in recent years, the overall development momentum of China's pharmaceutical industry has been good.
The industry has previously predicted that during the "14th Five-Year Plan" period, China's pharmaceutical industry will usher in a period of policy dividend opportunities
.
From the current point of view, Daxing District is only a microcosm of the promotion of the further development of the pharmaceutical industry in China, and various localities are currently issuing policies that are beneficial to the development of the pharmaceutical industry
.
For example, on November 1, Jiangsu Province’s "Several Policy Measures on Promoting the High-Quality Development of the Provincial Biomedical Industry" was formally implemented, which clearly stated that in the next three years, it will provide financial support for the innovation of biomedical enterprises in the province
.
For example, in the development of new drugs, different levels of support will be given to innovative drugs and improved new drugs according to different clinical trial stages and marketing production stages; clinical research will be included in the performance evaluation of medical institutions, and for hospitals that have obtained the qualifications of clinical trial institutions, by 2024 In 2010, the proportion of clinical research beds in the total number of hospital beds increased to about 10%; support the introduction of the world’s best talents and teams, and project funding of up to 100 million yuan
.
On November 19, Shenzhen also announced the "Several Measures for Promoting the Development of Biomedical Industry Clusters in Shenzhen (Draft for Solicitation of Comments)" (hereinafter referred to as "Several Measures")
.
"Several Measures" show that Shenzhen will consolidate the support capacity of industrial infrastructure, improve product development support, strengthen clinical research transformation and medical-enterprise collaboration, accelerate the process of medical approval, enhance the "Made in Shenzhen" capability, and accelerate the application and promotion of innovative products.
Strengthen industrial clusters
.
In order to further encourage product development and manufacturing, "Several Measures" also clearly stated that it will increase product development support and focus on breaking new targets.
Chemical drugs, antibody drugs, gene therapy drugs, cell therapy drugs, peptide drugs and enzyme engineering, AI drug development chips Such core technologies, using the "horse racing system", "revealing the list system" and other methods, support enterprises to cooperate with universities and scientific research institutes to carry out "stuck neck" technical research.
Funding will be based on 40% of the total project investment, and the maximum will not exceed 300 million yuan
.
It should be noted that while the pharmaceutical industry is ushering in an increasingly broad market prospect, the industry believes that the challenges it faces will continue to increase
.
For example, the regulation faced by the pharmaceutical industry is becoming more stringent
.
It is reported that medicines are important products related to the health of the people, and it has become the consensus of all regions to strengthen supervision over them
.
Especially after the release of policies such as the withdrawal of GMP, GSP certification, and the "Measures for Unannounced Inspection of Drugs and Medical Devices" in 2019, it can be clearly seen that the country and even local governments are also moving towards standardization in all aspects of drug research and development to sales.
Accelerate development
.
